Page 59 - NPPA full book

Plants and Machinery commissioned under PLI-Bulk Drugs Scheme

The second PLI for pharmaceu cals was launched in March, 2021 with the objec ve of enhancing the manufacturing

capabili es of this sector by fostering investments in high end R&D and product diversifica on towards high value
drugs. This PLI covers three categories of pharmaceu cals:

Biopharmaceu cals; Complex generic drugus; Patented drugs nearing patent expiry;

Category Cell based or gene therapy drug; Orphan drugs; Special empty capsules; complex
01 escipients; Phyto-pharmaceu cals;

Globela Industries, Gujarat (Products: Emmennar Pharma, Telangana (Products: Meghmani LLP, Gujarat (Products: Category Ac ve Pharmaceu cal Ingredients/Key Star ng materials/Drug Intermediates
02
Norfloxacin and Ofloxacin) Cyclohexane Diace c Acid) Para Amino Phenol)

Plants and Machinery commissioned under PLI - Pharmaceu cals Scheme (Drugs not covered in Category 1 and 2) : Repurposed drugs; Auto immune drugs,

an -cancer drugs, an -diabe c drugs, an -infec ve drugs, cardiovascular drugs,
Category psychotropic drugs and an -retrovial drugs; In vitro diagnositc devices; Other drugs
03 not manufactured in India etc.

In PLI scheme for Bulk Drug, 48 projects have been selected for 41 iden fied bulk drugs, out of which 24 projects have been
commissioned ll 31.3.2023. The PLI Scheme for Pharmaceu cals was expected to bring in investment of more than Rs. 17,000

crore (US$ 2.07 billion approx) to promote high-value drug making and increase the value addi on in exports. Actual investment

of Rs. 20400 crore (US$ 2.49 billion approx) has already been made by 55 par cipants under the scheme.

Emcure Pharmaceu cals, Plant-Pune Dr. Reddy’s Labs, Plant-Hyderabad Biocon Limited, R&D Centre-Chennai
Scheme for Promotion of Bulk Drug Parks

With a natural extension of preceding policies aimed at reducing import dependence, the Government of India has come up

with a scheme for Promo on of Bulk Drug Parks. API pharma companies are provided support as pharma clusters with common
infrastructure facili es under Assistance to Pharmaceu cal Industry for world-class Common Facili es (API-CF). The financial

assistance has been given for establishing three Bulk Drug Parks in Himachal Pradesh, Andhra Pradesh and Gujarat. The aim is to

ensure uninterrupted produc on and lowering the cost of produc on. The parks will host common facili es like solvent
recovery plant, dis lla on plant, power & steam units, and a common effluent treatment plant.

Emcure Pharmaceu cals, Plant-Pune Abhilash Life Sciences, Plant-Bengaluru Cipla Ltd. (Plants-Sikkim)

48 49